Chronic Kidney Disease (CKD) Clinical Trial
Official title:
A Prospective, Open Label, Single Arm, and Multicenter Study to Evaluate Immunogenicity of Epodion in Anemia Associated With Chronic Kidney Disease (CKD) Patients
Verified date | July 2022 |
Source | PT. Daewoong Infion |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The study was conducted to assess safety and immunogenicity of recombinant human erythropoietin (rhEPO) manufactured by Daewoong Pharmaceutical Co., Ltd was similar to biological products approved by the drug safety regulatory authority.
Status | Completed |
Enrollment | 200 |
Est. completion date | November 30, 2020 |
Est. primary completion date | November 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients who have anemia associated with Chronic Kidney Disease (CKD) under hemodialysis treatment. - Male or female patients aged =18 years. - Patients with mean Hb concentration when screening is around =10 g/dL. - Patients on stable, adequate dialysis for at least three months (defined as no clinically relevant changes of hemodialysis regimen and/or 23/42 ©EMEA 2007 dialyzer). - Has ever been using Epodion treatment in the at least last 1 month. - Haemodialysis patients who likely to remain on Epodion treatment for 52 weeks. - Informed consent given in a written form after being provided with detailed information about the nature, risks, and scope of the clinical trial as well as the expected desirable and adverse effects of the drug. Exclusion Criteria: - History of Pure Red Cell Aplasia (PRCA) or anti-epoetin antibodies. - Contraindications for ESA therapy. - Systemic immunosuppressive medication or any other drugs known to adversely affect the hemoglobin level. - History of uncontrolled hypertension (defined as systolic blood pressure =180 mmHg or diastolic blood pressure =110 mmHg during screening). - Any blood transfusion within the last 2 weeks prior to screening period. - Major surgery within 3 months prior to screening period. - Myelodysplastic syndrome. - History bleeding disorders (e.g. Hemophilia, Von Willebrand, and any conditions that result when the blood cannot clot properly). - Known bone marrow fibrosis (osteitis fibrosa cystica). - Known epilepsy. - Liver cirrhosis with clinical evidence of complications (portal hypertension, splenomegaly, ascites). - Systemic lupus erythematosus. - Previously diagnosed with HIV or acute hepatitis infection. - History of malignancy of any organ system within the last 5 year. - Pregnancy or lactation period in female patients. - Heavy smoker (who smoke over 20 cigarettes daily in average). |
Country | Name | City | State |
---|---|---|---|
Indonesia | Gatot Soebroto Army Hospital | Jakarta | DKI Jakarta |
Lead Sponsor | Collaborator |
---|---|
PT. Daewoong Infion | Equilab International |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Anti-Erythropoietin Antibodies (ADA) formation at week 52nd | to evaluate if there is any incidence of ADA formation on the blood sample | week 52 | |
Primary | Neutralizing Antibodies detection (Nab) (will be assessed if ADA is positive). | to evaluate the neutralizing effect of the detected ADA using cell-based assay method to confirm the impact of the antibody to pharmacological activity. | week 52 | |
Secondary | Any Adverse Event | to evaluate any adverse event related to the test product during study | 52 weeks | |
Secondary | Incidence of Anti-Erythropoietin Antibodies (ADA) formation at week 24th | to evaluate if there is any incidence of ADA formation on the blood sample | week 24 | |
Secondary | Comparison on the incidence of Anti-Erythropoietin Antibodies (ADA) formation at week 24th and week 52nd. | to evaluate the neutralizing effect of the detected ADA using cell-based assay method to confirm the impact of the antibody to pharmacological activity. | week 24 and 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Recruiting |
NCT04064827 -
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02218099 -
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02276742 -
Lifestyle Management of CKD in Obese Diabetic Patients
|
N/A | |
Completed |
NCT01222234 -
Impact of Vitamin D Therapies on Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT05106387 -
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive A Kidney Transplant
|
||
Completed |
NCT05373303 -
The Clinical Study for Evaluating The Safety And Efficacy Of Epodion®
|
N/A | |
Completed |
NCT01247311 -
Vitamin D and the Health of Blood Vessels in Kidney Disease
|
N/A | |
Completed |
NCT04042350 -
Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis
|
||
Completed |
NCT02733328 -
Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
|
||
Completed |
NCT02341664 -
Patient and Provider Assessment of Lipid Management Registry
|
||
Enrolling by invitation |
NCT06322641 -
A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists
|
||
Completed |
NCT05755373 -
A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists
|
||
Completed |
NCT02678000 -
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
|
Phase 2 | |
Completed |
NCT02185911 -
Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis
|
N/A | |
Terminated |
NCT03226899 -
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
|
Phase 4 | |
Completed |
NCT02504294 -
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Active, not recruiting |
NCT04094831 -
Community-based Screening of Chronic Kidney Disease (CKD) and Measure the Impact of Health Education
|
N/A | |
Completed |
NCT01810939 -
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
|
Phase 3 | |
Enrolling by invitation |
NCT06447038 -
Pilot Study for the Early Detection of Chronic Kidney Disease, Non-Dialysis Objective (NDO).
|